128 related articles for article (PubMed ID: 38432338)
1. Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes.
Singh S; Garg A; Tantry US; Bliden K; Gurbel PA; Gulati M
Am J Cardiol; 2024 May; 218():24-31. PubMed ID: 38432338
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY
PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654
[TBL] [Abstract][Full Text] [Related]
4. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
5. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
[TBL] [Abstract][Full Text] [Related]
6. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
7. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
[TBL] [Abstract][Full Text] [Related]
8. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Patel SM; Kang YM; Im K; Neuen BL; Anker SD; Bhatt DL; Butler J; Cherney DZI; Claggett BL; Fletcher RA; Herrington WG; Inzucchi SE; Jardine MJ; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Solomon SD; Staplin N; Vaduganathan M; Wanner C; Wheeler DC; Zannad F; Zhao Y; Heerspink HJL; Sabatine MS; Wiviott SD
Circulation; 2024 Jun; 149(23):1789-1801. PubMed ID: 38583093
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Zelniker TA; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS;
N Engl J Med; 2019 Jan; 380(4):347-357. PubMed ID: 30415602
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
Arbel R; Aboalhasan E; Hammerman A; Azuri J
Am J Cardiol; 2021 Jul; 150():65-68. PubMed ID: 34001339
[TBL] [Abstract][Full Text] [Related]
11. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
[TBL] [Abstract][Full Text] [Related]
13. Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials.
Eraikhuemen N; Leung S; Warren SB; Lazaridis D; Smith CH; Kearson ML; Marcellus V
Am J Cardiovasc Drugs; 2023 Mar; 23(2):113-126. PubMed ID: 36572841
[TBL] [Abstract][Full Text] [Related]
14. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
[TBL] [Abstract][Full Text] [Related]
16. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
Täger T; Frankenstein L; Atar D; Agewall S; Frey N; Grundtvig M; Clark AL; Cleland JGF; Fröhlich H
Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169
[TBL] [Abstract][Full Text] [Related]
17. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
18. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
[TBL] [Abstract][Full Text] [Related]
19. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
McGuire DK; Shih WJ; Cosentino F; Charbonnel B; Cherney DZI; Dagogo-Jack S; Pratley R; Greenberg M; Wang S; Huyck S; Gantz I; Terra SG; Masiukiewicz U; Cannon CP
JAMA Cardiol; 2021 Feb; 6(2):148-158. PubMed ID: 33031522
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
